Previous 10 | Next 10 |
home / stock / konef / konef news
New Clinical Facility in London, Ontario Accelerates Research and Innovation Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company ...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
KetamineOne Capital press release ( OTCQB:KONEF ): Q4 Revenue of C$1.16M (+2.7% Y/Y). Net loss for the quarter ended July 31, 2022 was $4,056,632. For further details see: KetamineOne Capital reports Q4 results
Revenue Exceeded $1.1 Million for the Period Ended July 31, 2022 Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on t...
KGK client, Hofseth Biocare ASA, is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Acknowledgement (AKL) Letter for ProGo® Bioactive Peptides Wellbeing Digital Sciences Inc. (“ Wellbeing...
IRP Health continues to focus on enriching the lives of its patients and raising the bar for outstanding mental healthcare Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an...
Subsidiary KGK has $17 million of future revenue as of end of June, which we project to complete in the next 12 to 18 months through our research and consulting contracts, with $10-11 million to be billed in the next 12 months Wellbeing Digital Sciences Inc. (“ ...
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ) has filed the required notice to change its financial year end from July 3...
KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on treatment resistant PTSD Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-ba...
VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and impl...
News, Short Squeeze, Breakout and More Instantly...
KetamineOne Capital Limited Company Name:
KONEF Stock Symbol:
OTCMKTS Market:
KetamineOne Capital Limited Website:
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...
Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) ( NEO: MEDI ) ( OTC: KONEF ) ( FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psych...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...